This is a new method for genome editing gamma delta T cells to generate off-the-shelf gamma delta CAR-T cells for cancer immunotherapies. The approach utilizes Cas9/RNP and AAV to achieve highly efficient gene knockout and site-directed gene and CAR insertion in gamma delta T cells. The process involves the use of mb-IL21 expressing feeder cells for the expansion of gene-edited cells. This is a significant advancement in the field, with potential applications in cancer immunotherapy, and further development aims to validate the antitumor activity of these cells in vitro and in vivo.